LIGAND PHARMACEUTICALS INC — Director's Dealing 2018

Sep 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2018-09-04

Reporting Person: Berkman Charles S (SVP, Gen. Counsel & Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-04	Common Stock	M	469	$21.92	Acquired	28232	Direct
2018-09-04	Common Stock	M	5985	$74.42	Acquired	34217	Direct
2018-09-04	Common Stock	M	7077	$56.26	Acquired	41294	Direct
2018-09-04	Common Stock	M	5886	$85.79	Acquired	47180	Direct
2018-09-04	Common Stock	S	19417	$254.9861	Disposed	27763	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-04	Employee Stock Option (right to buy)	$56.26	M	7077	Disposed	2025-02-10	Common Stock (7077)	Direct
2018-09-04	Employee Stock Option (right to buy)	$74.42	M	5985	Disposed	2024-02-12	Common Stock (5985)	Direct
2018-09-04	Employee Stock Option (right to buy)	$85.79	M	5886	Disposed	2026-02-11	Common Stock (5886)	Direct
2018-09-04	Non-Qualified Stock Option (right to buy)	$21.92	M	469	Disposed	2023-02-15	Common Stock (469)	Direct

Footnotes

F1: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.59, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15.

F4: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14.

F5: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16.

F6: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.